HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Triiodothyronine; clinical effects in patients with suboptimal response to other thyroid preparations.

Abstract
Thirty patients with evidence of hypometabolism or a clinically related condition were given triiodothyronine after suboptimal response to thyroxin or desiccated thyroid. DL- and L-isomers of triiodothyronine were used and compared. Thirteen patients (43.3 per cent) were improved and 17 (56.6 per cent) were unimproved or became worse. Side effects occurred in 9 of 34 trials (26 per cent), and could not always be eliminated by decreasing the dosage. The highest percentage of good response occurred in a small group (four of five) who received a combination of desiccated thyroid or thyroxin with supplemental triiodothyronine. Despite careful analysis of the data, no basis was found on which to predict which patients would receive benefit from the triiodothyronine. However, the occasional improvement, sometimes dramatic, suggested that a therapeutic trial with triiodothyronine in difficult or unresponsive cases of hypometabolism or hypothyroidism is justified.
AuthorsS NEWMAN, R F ESCAMILLA
JournalCalifornia medicine (Calif Med) Vol. 88 Issue 3 Pg. 206-10 (Mar 1958) ISSN: 0008-1264 [Print] United States
PMID13511212 (Publication Type: Journal Article)
Chemical References
  • Antineoplastic Agents, Hormonal
  • Triiodothyronine
  • Thyroxine
Topics
  • Antineoplastic Agents, Hormonal
  • Basal Metabolism
  • Humans
  • Hypothyroidism (therapy)
  • Thyroxine
  • Triiodothyronine (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: